![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 8 to 11 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.281 |
Chemical and physical data | |
Formula | C19H15NO6 |
Molar mass | 353.330 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
Melting point | 196 to 199 °C (385 to 390 °F) |
| |
| |
(verify) |
Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is generic, so is marketed under many brand names worldwide.[1]
References
- ^ "International listings for acenocoumarol". Drugs.com.
Further reading
- Cesar JM, García-Avello A, Navarro JL, Herraez MV (October 2004). "Aging and oral anticoagulant therapy using acenocoumarol". Blood Coagulation & Fibrinolysis. 15 (8): 673–676. doi:10.1097/00001721-200412000-00007. PMID 15613922. S2CID 19214006.
- Lengyel M (December 2004). "[Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]". Orvosi Hetilap. 145 (52): 2619–2621. PMID 15724697.
- Ufer M (2005). "Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol". Clinical Pharmacokinetics. 44 (12): 1227–1246. doi:10.2165/00003088-200544120-00003. PMID 16372822. S2CID 42970169.
- Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J (April 2006). "The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients". British Journal of Haematology. 133 (2): 183–187. doi:10.1111/j.1365-2141.2006.06007.x. hdl:10171/21989. PMID 16611310. S2CID 369821.
External links
- Diseases Database (DDB): 29202